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Abstract 
Spec1fic problems are posed by med1cated prem1xes : stability of the active ingredient, 
homogeneity of the medicated prem1x distribution in the feed and cross-contammation due to dust 
emission These problems can have two major consequences· a treatment failure and a risk for 
human health with selection of res1stant stra1ns CEVA Matrix Technology m, an exclusive CEVA 
Sante Ammale manufacturing process, matches all expectations of an effective and modern 
medicated premix. CEVA Matrix Technologym consists of an innovative protective granulation 
technology Most non-protected medicated prem1xes available in the market do not provide good 
stability and may not reach effic1ent concentration as the active 1ngred1ent 1s not protected enough. 
F1rst, the CEVA Matrix Technologym guarantees that the active ingredient is protected dunng 
manufacture (pellet1ng) and storage of the medicated feed w1thout altenng 1ts bioavailab11ity 
Secondly, the part1cle s1ze of CEVA Matnx Technologym premixes IS s1m1lar to the feed 1n wh1ch 1t 
IS to be blended Therefore the active mgredient is mixed homogeneously into the feed and 
remains homogeneous even after transportation and storage Th1s perfect mixability ensures the 
right act1ve 1ngred1ent concentration and dosage 1n feed every t1me Consequently, treatment 
fa1lure resulting from unequal dosage distribution of the active ingredient in the feed is considerably 
limited Thirdly, CEVA Matrix Technologym guarantees that the prem1x does not release dust. 
Therefore, 1t reduces nsks such as cross contam1nat1on between two medicated feed batches 1n 
m1lls and inhalation of antimicrobial by users. It protects the workforce and reduces the risk of 
selectmg res1stant strams Th1s art1cle validates all these p01nts by companng a t1amuhn medicated 
premix manufactured with the CEVA Matrix Technologym and some non-protected tiamulin 
Introduction 
CEVA Matnx Technologym, an 1nnovat1ve protective granulation technology, brings a solut1on to 
the specific problems posed by medicated premixes stab1lity of the active ingredient, homogeneity 
of the med1cated prem1x distribution m the feed and cross-contammat1on due to dust em1ss1on. The 
objectives of this study are to compare stability, homogeneity and dust emission of a tiamulin 
prem1x (T1amvet®) manufactured w1th Matnx Technologym to others 
Materials and methods 
Stability of the active ingredient 
An HPLC method was developed and validated for determination of llamulin m creep and pelleted 
feed The eqUipment used for the vahdat1on was an HPLC system Sh1madzu LC-10 AD VP, w1th a 
diode array detector Through a reverse phase column and a mixture of the appropriate solvent it 
1s poss1ble to separate the substance from the other components present 1n the feed and make the 
quantitative determination by comparing the peak area of the sample with the peak area of a 
reference solution with a known content of Tiamulin hydrogen fumarate The chromatographic 
conditions are listed below· 
Column Hypersil ODS, 250 x 4 mm 5 1Jm 
ob1le phase (MeOH/ACN/1% ammonium carbonate) (50/30/20) (VNN) 
Control pH at 8 9 0 1 
- Flow rate 1 0 mVmin 
- U.V. detection. 250 nm 
- Injected olume: 20 IJI 
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Granulometry 
In order to evaluate the "in feed homogeneity" the part1cle s1ze of three different medicated 
prem1xes was measured. The equipment used was an Octagon test s1eve shaker 
The method IS descnbed below 
- We1gh about 100 g of the product under test and transfer above a senes of mne sieves with 
d1fferent aperture s1zes. Start s1evmg with Octagon test s1eve shaker 
- Operat1ve condition . 
Accommodate the selected s1eves (no 9) of 200 mm diameter and the rece1ver on the centre of 
shaker locat1on and stack them on the top of the rece1ver 
Place the clamp plate on the top of the s1eve located the two holes over an hexagonal rods 
Tighten w1th two handles firmly 
Start shaker vibration for 10 minutes. 
Results. 
After the test, collect and we1gh the amount settled on each s1eve and calculated the % of the total 
deposited amount. 
Dust emission 
The total powders are determmed through dust meter Heubach of specific type II for the fine 
powder tenor (fraction depos1ted on the filter less than 10 IJm) in granular powders 
Pnnc1ple of the method 
The test s1mulates the conditions that are taken place m the course of the production of feeds 
(we1ghmg, m1x1ng, transport, handling) and represents an obJeCtive method for the measurement of 
fine powders in granular powders The product (100 g) is placed in the stress room that turns at 
30 r p m. and 1t IS st1rred from a set of rotary shovels In the same room, a1r IS mtroduced, 
generated from a calibrated vacuum pump (standard flow 20 htre/mmute for 5 mmutes) and the 
produced powders are spread along the system The part1cles of greater dimens1ons are 
separated to level of the first elbow and the subsequent rooms of separation, wh1le those finer 
(under to the 10 1-1m) are deposited on the terminal filter m glass fibre ( 0 50 mm) 
Calculation 
The total powders are calculated according to the followmg formula 
mg/f11ter = we1ght of the filter m mg (after test) - we1ght of the filter in mg (time zero) 
The formula expresses the mglfilter for 1 00 g of product 
Results and Discussion 
Stabtflly study 
The two products performed differently in pelleted feed (Figure 1) After three months of storage, 
active 1ngred1ent concentration for the tiamulin w1thout Matrix TechnologyTM is 60 % of the imt1al 
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Figure 1 Stab1hly of tiamulin 1n pelleted feed W 25 C I RM 60 °'o) 
active ingredient concentration. With the protection of the Matrix Technologyn", the active 
ingredient concentration remains stable even after three months of storage (95 % of the initial 
value). 
Homogenetly study 
In order to ensure a good homogenisation, the main criterion is the granulometry of medicated 
prem1xes. Actually, the Simplest solut1on to ensure effective homogenisation of the active 
ingred1ent in the feed and to avoid dem1xing is to use a medicated premix whose particles are the 
same size as those of the swine feed. A previous study, conducted by CEVA Sante Animale on 
fifteen batches of swine feed from seven different countnes has shown that more than 70% of the 
swine feed consists of gra1ns whose s1ze is higher than 300 11m with an average grain size of 700 
to 900 ~1m . On the three tiamulin prem1xes tested, the t1amulin prem1x with Matrix Technology™ is 
the only one with a huge percentage of grains whose size is h1gher than 300 11m (Table 1 ). 
Grain size (~m) < 45 45-63 63-90 90-100 1 00-150 150-300 > 300 
Tiamvet® 0% 0% 0% 0% 0% 1% 99% 
Product A 10% 36.4% 22.1% 13.4% 5.6% 8.4% 4.1% 
Product B 0.3% 4.5% 6% 10.9% 19.5% 46% 12.8% 
Table 1 Granulometry of three tiamulin prem1xes 
A second granulometry study with higher grain size tested has be done on the t1amulin premix w1th 
Matnx Technology™ The results show that the gram size of a tiamulin prem1x w1th Matnx 
Technology™ 1s cons1stent with the spec1fic granulometry of sw1ne feed (Figure 2). We can 
therefore conclude that this medicated premix will have a good homogenisation in swine feed. 
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Figure 2 Granulometry of a t1amulin premix w1th Matnx Technology,..,. 
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Dust emission study 
The dust emission of the three tiamulin premixes is radically different (Figure 3). The tlamulin 
premtx w1th Matnx Technology™ emits 0.1 mg of dust for 100 g of product, mak1ng it a med1cated 
prem1x w1th a very low level of dust em1ss1on. The two other products tested em1t respectively 4326 
and 9276 more dust, mak1ng them a medicated premix with a very high level of dust emission and 
with the inherent risks of cross-contammat1on and of inhalation of active ingredient by the 
operators. 
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Conclusion 
CEVA Matnx Technology TM 1s a global solution to answer all the problems posed by medicated 
premixes 
- very good stability of the act1ve ingredient dunng manufacture (pellet1ng) and storage of the 
medicated feed (without altering the bioavailab11ity) 
- part1cle s1ze s1milar to the feed in wh1ch 11 is to be blended allowmg a perfect m1xab1lity 
- very low dust level em1ss1on ( < 2 mg / 1 00 g of product) 
Consequently, CEVA Matrix Technology™ enables to 
- avoid treatment failure due to incorrect active ingredient concentration 
- lim1t the nsk of select1ng resistant strains due to low active mgred1ent concentration 
- protect the workforce (no dust emission) 
- avoid cross-contammat1on of batches 
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